Effect of dexmedetomidine on cognition, immune inflammatory reaction and oxidative stress in lung cancer patients with VATS / 中国基层医药

ABSTRACT

Objective@#To investigate the effect of dexmedetomidine on cognition (MMSE score), immune inflammatory reaction and oxidative stress in lung cancer patients with VATS.@*Methods@#From January 2016 to December 2017, 89 lung cancer patients underwent VATS in the Second Hospital of Qinhuangdao were randomly divided into the control group (n=46) and the dexmedetomidine group (n=43) according to the digital table.The MMES, CD4 and CD8 lymphocytes, inflammatory factors and oxidative stress factors were compared between the two groups before operation (T0) and at 3 hours (T1), 12 hours (T2), 24 hours (T3) after operation.@*Results@#There were no statistically significant differences in MMSE, CD4 and CD8 lymphocytes, inflammatory factors and oxidative stress factors between the two groups (P>0.05). At the time points of T1, T2 and T3, MMSE scores decreased in both two groups, but the MMSE score in the dexmedetomidine group was higher than those in the control group [(27.67±1.97)points vs.(25.61±1.81)points, (26.47±1.92)points vs.(24.70±2.26)points, (26.16±1.90)pouints vs.(23.41±2.33)points, t=-2.122, -2.553, -2.528, P=0.037, 0.012, 0.013]. The CD8 lymphocyte, inflammatory factors and oxidative stress factors increased after operation in both two groups, and dexmedetomidine could inhibit the increase of immune inflammatory factors and oxidative response factors(IL-6 t=3.038, 2.489, 3.291, P=0.003, 0.015, 0.001; hsCRP t=2.147, 2.164, 2.752, P=0.035, 0.033, 0.007; TNF-α t=2.119, 2.323, 2.485, P=0.037, 0.023, 0.015; MDA t=2.499, 2.116, 2.094, P=0.014, 0.037, 0.039; MPO t=2.190, 2.166, 2.849, P=0.031, 0.033, 0.005; SOD t=-2.551, -2.598, -3.141, P=0.012, 0.011, 0.002). The incidence rate of adverse reactions in dexmedetomidine group was lower than that in control group(6/43 vs.18/46, P=0.011).@*Conclusion@#Dexmedetomidine can improve cognition, reduce immune inflammatory reaction and oxidative stress, and alleviate adverse effects in lung cancer patients with VATS.